E
Stand out from Crowd

Which therapies will stand out in the CLL market?

New CLL therapies that stand out in a rapidly changing CLL landscape include obinutuzumab (Gazyva), ibrutinib (Imbruvica) idelalisib (Zydelig), ABT-199/GDC-0199 and CTL019.

July 30, 2014
E
Antoni Ribas ASCO 2014 Melanoma

What impact will nivolumab & pembrolizumab have on advanced melanoma?

How will we decide which therapies to give patients with metastatic melanoma once the new immunotherapies are available?

July 23, 2014
E
Another Place

ASCO 2014 Update on the AML landscape

There are a number of new targets, therapies and approaches in AML being investigated but which ones look most promising in this challenging landscape?

July 17, 2014
E
ABT-199 single agent in R/R CLL from ASCO 2014 Abstract 7015 Source: Roche

ASCO 2014 Will ABT-199 change the CLL landscape?

After a few setbacks in clinical development, some solid data is emerging with AbbVie/Genentech's ABT-199/GDC-0199 in CLL. Some more mature data at ASCO was very encouraging...

July 14, 2014
E
ASCO 2014 Chicago Contemplation

ASCO 2014 New horizons in DLBCL and aggressive lymphomas

Diffuse large B cell lymphomas (DLBCL) are an aggressive subset of non-Hodgkins lymphomas that generally have a poor prognosis and a high unmet medical need. There is a raft of promising new therapies being evaluated for treatment.

July 9, 2014
E
ASCO 2014 The Bean Chicago

ASCO 2014 blinatumomab in B cell ALL

Initial phase 2 data for Amgen's blinatumomab in B cell ALL looked encouraging 2 years ago but has it held up over time?

July 1, 2014
E
ASCO 2014 Meeting Logo

ASCO 2014 Diffuse Large B Cell Lymphoma DLBCL Progress

Several new agents in development emerged for the treatment of aggressive NHL (DLBCL and FL), including SGN-CD19A, polatuzumab vedotin and pinatuzumab vedotin.

June 30, 2014
E
ASCO 2014 General Poster Hall

ASCO 2014 Gems from Poster Hall part 2

A review of poster data at ASCO 2014 for new drugs from new cancer drugs from $CLDX, $OMED & NuCana BioMed.

June 27, 2014
E
ASCO 2014 Poster Hall

Gems from the ASCO 2014 Poster Hall – Part 1

Selection of some of the many posters that caught our attention. Companies whose products are mentioned include: $EXEL, $RHHBY, $XLRN, $MRK

June 24, 2014
E
Kite Pharma Banner

Kite Pharma Challenges and Opportunities Post-IPO $KITE

After it's successful IPO, what are some of the challenges and opportunities facing Kite Pharma and their CAR-T cell immunotherapy?

June 23, 2014
E
ASCO 2014 Crowds

AstraZeneca MEDI4736 shows Immuno-Oncology promise at ASCO 2014

AstraZeneca showed impressive data at ASCO 2014 for MEDI4736, a new anti PD-L1 immunotherapy.

June 19, 2014
E
Chicago Board of Trade Building

Making a difference in advanced bladder cancer

There have been no new therapies in urothelial bladder cancer for 30 years - until now...

June 17, 2014
E
Chicago Art Institute

ASCO 2014 Nivolumab vs Pembrolizumab in Metastatic Melanoma

PD-1 antibodies nivolumab and pembrolizumab show considerable promise in metastatic melanoma. At ASCO 2014 we learnt more about how they compare against each other and their potential as a backbone for combinations.

June 16, 2014
E
ASCO 2014 Chicago the Bean

Combination strategies for nivolumab in Renal Cell Carcinoma

What does the ASCO 2014 data show when you combine checkpoint inhibitors nivolumab and ipilimumab?

June 13, 2014
E
ASCO 2014 Poster Hall

ASCO 2014 What do oncologists think of PARP inhibitors?

With the intense focus on immino-oncology, are targeted agents passe now?

June 11, 2014
E
View of downtown Chicago

A potential new target for prostate cancer drug development

A predictive biomarker for resistance to treatment by enzalutamide and abiraterone may lead to new prostate cancer drug development opportunities.

June 9, 2014
E
Clovis CO-1686 ASCO 2014

Why Clovis CO-1686 was not an ASCO 2014 loser

Clovis Oncology CO-1686 is in competition with AstraZeneca's AZD9291, but was it really a "loser" at ASCO 2014 as many think it was?

June 6, 2014
E
ASCO 2014 Arie Crown

ASCO 2014 Day 5 Live Blog #ASCO14

Final day at ASCO 2014 - what are the diehards listening to this morning?

June 3, 2014
E
Bertrand Tombal ASCO 2014

ASCO 2014 Annual Meeting Live Blog Day 4 #ASCO14

Live blog with commentary on Day 4 of the ASCO 2014 annual meeting in Chicago.

June 2, 2014
E
ASCO 2014 Poster Hall

ASCO 2014 Meeting Day 3 Live Blog #ASCO14

Live blog with updates from Day 3 at ASCO 2014

June 1, 2014
E
View of Chicago

ASCO 2014 Day 2 Live Blog #ASCO14

Live Blog from Day 2 of ASCO 2014 in Chicago.

May 31, 2014
E
ASCO 2014 View of Lake Michigan

ASCO 2014 Chicago Day 1 Blog #ASCO14

Coverage of day 1 at ASCO 2014 with commentary on some of the poster highlights.

May 30, 2014
E
ASCO 2011 #BlisterWalk

ASCO 2014 CLL and iNHL Preview #ASCO14

Update on the top drugs in CLL including ibrutinib, obinutuzumab, idelalisib, ABT-199, GS-9973, ONO-4059, CTL019, TAK659, IPI-145, cerdulatinib and others.

May 28, 2014
E
Panobinostat, a deacteylase inhibitor from Novartis

ASCO 2014 Multiple Myeloma Preview #ASCO14

Highlights in multiple myeloma at ASCO include drugs with a different mechanism of action eg panobinostat, daratumumab and elotuzumab, #ASCO14

May 27, 2014
E
View of Chicago and the Bean

ASCO 2014 Preview #1: When triple combinations make sense

How we could overcome resistance to BRAF inhibitors in colon cancer with a triple combination approach

May 15, 2014